7 CFU of overnight cultures into 3-ml vials of brain heart infusion broth supplemented with increasing concentrations of vancomycin, and growth-related heat production was measured at 37°C. For the reference strains, no heat production was detected in the VSSA isolates at vancomycin concentrations of >3 g/ml during the 72 h of incubation. The hVISA and VISA strains showed heat production with concentration-proportional delays of up to 6 g/ml in 48 h and up to 12 g/ml in 72 h, respectively. The VRSA strain showed heat production at concentrations up to 16 g/ml in 12 h. The testing of clinical strains indicated an excellent negative predictive value, allowing us to rule out a decreased vancomycin susceptibility phenotype in <8 h of incubation. Sequential isolates from a patient undergoing vancomycin therapy showed evolving microcalorimetric profiles up to a VISA phenotype. Microcalorimetry was able to detect strains with reduced susceptibilities to vancomycin in <8 h. The measurement of bacterial heat production might represent a simple and rapid method for the detection of reduced susceptibilities to vancomycin in MRSA strains.
V
ancomycin remains one of the first-line treatment options for severe infections caused by methicillin-resistant Staphylococcus aureus (MRSA). In the last decade, MRSA with reduced susceptibility or resistance to vancomycin has emerged. Vancomycin-resistant S. aureus (VRSA) strains have developed resistance by the acquisition of the vanA operon from enterococci, and they have expressed high-level resistance to vancomycin with MIC values of Ն16 g/ml. The first VRSA strain was described in 2002 (1) , and to date, more than 30 VRSA cases have been described worldwide (2) (3) (4) . On the other hand, a larger number of S. aureus strains have also acquired lower, albeit clinically significant levels of reduced vancomycin susceptibility, the mechanisms of which are not yet fully characterized (2) . Depending on their phenotypes, these strains are labeled either as heterogeneous vancomycin-intermediate S. aureus (hVISA) or homogeneous vancomycin-intermediate S. aureus (VISA). Whereas in VISA, nearly the whole bacterial population exhibits an increased vancomycin MIC, in hVISA, only a subset of the population, typically at a frequency of 10 Ϫ4 to 10 Ϫ6 , exhibits an increased vancomycin MIC. The first detection of hVISA and VISA strains was reported in Japan in 1997 (5, 6) . A number of studies have shown that infections with hVISA and VISA strains have poorer clinical outcomes when vancomycin is used, but their exact prevalence is unclear, essentially because of a lack of standardized detection methods and changes in clinical breakpoints over the years (2, 7, 8) . Within MRSA, the prevalences of hVISA and VISA have been estimated to range from 0 to 10% (2) . In that context, the clinical breakpoints for vancomycin established by the European Committee on Antimicrobial Susceptibility Testing (EUCAST) or the Clinical and Laboratory Standards Institute (CLSI) have recently been lowered in order to achieve a better detection of these isolates (9) (10) (11) .
Therefore, it is of the utmost importance that S. aureus strains exhibiting decreased susceptibilities to glycopeptides be identified in a timely manner in order for the patient to benefit from the use of alternative anti-MRSA agents.
Due to their high vancomycin MICs, the detection of VISA (MIC, 4 to 8 g/ml) or VRSA (MIC, Ն16 g/ml) is relatively straightforward using conventional microbiological techniques, such as Etest strips or disk diffusion testing. In contrast, the detection of hVISA can be challenging due to its low-level vancomycin resistance and the presence of resistance in only a fraction of the population (12, 13) . Various methods have been described to increase the sensitivity of detection, such as vancomycin agar screening plates or Etest sensitivity testing using a high inoculum. All these methods demonstrate sensitivities ranging from 30% to 90%, with wide variations in specificity (see reference 2 for a review of the detection methods). The current gold standard is the population analysis profile (PAP), often performed in conjunction with an area under the curve (AUC) analysis (14) , but this technique is time-and labor-consuming and therefore not suit-able for routine use in clinical microbiology laboratories. Moreover, all these techniques often require 48 h of incubation to obtain reliable results. Isothermal microcalorimetry is based on the detection of heat produced by active biological processes, such as bacterial metabolism and replication (15) (16) (17) . In the present study, we developed a microcalorimetry-based approach to rapidly discriminate vancomycin-susceptible from -nonsusceptible phenotypes in MRSA strains.
MATERIALS AND METHODS
Bacterial strains, growth conditions, and antibiotics. The S. aureus strains used in this study are described in Table 1 . Bacteria were grown on either brain heart infusion (BHI) agar or BHI broth (Oxoid, Basingstoke, United Kingdom) at 37°C. Bacterial stocks were kept at Ϫ80°C in BHI broth supplemented with 10% (vol/vol) glycerol. Bacterial suspensions were freshly prepared from colonies harvested on BHI agar plates. Vancomycin powder was purchased from Eli Lilly (Geneva, Switzerland).
Conventional vancomycin susceptibility testing. The vancomycin MICs were determined by the Etest method (bioMérieux, Marcy l'Etoile, France) with a 0.5 McFarland standard inoculum. The MIC clinical breakpoints were defined according to the CLSI guidelines (susceptible, Յ2 g/ml; intermediate, 4 to 8 g/ml; and resistant, Ն16 g/ml) (9) .
Microcalorimetric vancomycin susceptibility testing. A 48-channel isothermal microcalorimeter (TAM III; TA Instruments, New Castle, DE, USA) was used to measure bacterial heat flow at 37°C. The detection limit of heat production of the instrument is 0.2 W (corresponding to 10 3 to 10 4 bacterial cells) with an absolute accuracy of 0.02°C. Microcalorimetric glass ampoules (volume, 4 ml) were filled with 3 ml of BHI broth containing increasing concentrations of vancomycin (arithmetic progression from 0 to 8, 12, and 16 g/ml). Each ampoule was subsequently inoculated with 100 l of a bacterial suspension diluted in normal saline to McFarland 2.0 standard (corresponding to approximately 5 ϫ 10 8 CFU/ ml). The ampoules were sealed and introduced into the microcalorimeter. The heat flow was recorded at 37°C for up to 72 h. Positive growth was defined as a heat flow of Ͼ20 W from baseline, and the time from inoculation to growth positivity detection was determined using the manufacturer's software (TAM Assistant; TA Instruments). All experiments were performed at least in triplicate.
Population analysis profiles. PAPs were carried out by spreading serial dilutions (10 Ϫ2 to 10 Ϫ7 ) of an overnight culture (ϳ10 9 CFU/ml) of the test strains on agar plates containing arithmetic progressions of vancomycin concentrations from 1 to 8 g/ml. The colonies were counted after 48 h of incubation at 37°C. Population analysis curves were drawn by plotting the number of colonies growing on the plates (expressed as log 10 CFU/ml) against the concentrations of vancomycin on the plates using GraphPad Prism (GraphPad, San Diego, CA, USA). The area under the curve (AUC) of the population analysis graph was calculated, and a ratio of the PAP/AUC of the tested isolates to that of the hVISA reference strain Mu3 was calculated (14) . PAP/AUC ratios of 0.9 to 1.3 and Ͼ1.3 were considered to be positive for hVISA and VISA, respectively (2) .
Genotyping. For genotyping, amplified fragment length polymorphism analysis was performed as previously described (18) .
RESULTS
Determination of vancomycin susceptibility profiles of reference strains by microcalorimetry. The typical heat flow curves obtained for the VSSA, hVISA, VISA, and VRSA reference strains grown in the presence of increasing concentrations of vancomycin are shown in Fig. 1 . The times to detection of the corresponding cultures are shown in Table 2 . Typical cumulated heat curves are provided in Fig. S2 in the supplemental material.
Heat flow curve profiles were clearly distinctive between the S. aureus strains exhibiting different levels of susceptibility to vancomycin. Whereas no difference in growth between all strains was seen in controls without antibiotic or with a vancomycin concentration of 1 g/ml, VSSA strains ATCC 29213 and ATCC 43300 exhibited growth only at 2 g/ml, with an important delay (Fig.  1A) . With the exception of a late positive signal of S. aureus ATCC 29213 at 3 g/ml after ca. 60 h, no further growth was observed at higher concentrations during the 72 h of incubation for either strain.
On the other hand, both hVISA strains (Mu3 and PC1) were able to grow at vancomycin concentrations up to 6 g/ml and 5 g/ml within 48 h, respectively (Fig. 1B) . Both VISA strains (Mu50 and PC3) grew at concentrations up to 8 g/ml in Ͻ24 h (Fig. 1C) . The VRSA strain SA510 grew at concentrations up to 16 g/m in less than 12 h (Fig. 1D) . Taken together, the time to detection results with a 20-W heat flow signal as a threshold allow for the establishment of cutoff values to rapidly segregate these reference strains into vancomycin-susceptible or -nonsusceptible phenotypes (Table 2 ). Since the longest detection time at a concentration of 2 g/ml ever obtained for hVISA was 7.7 h, if no positive growth signal at 2 g/ml occurred in the first 8 h of incubation, strains can be considered sensitive to vancomycin. In contrast, when a positive signal was detected at 2 g/ml, strains exhibited a vancomycin-nonsusceptible phenotype (i.e., hVISA, VISA, or VRSA). A strain that grew at concentrations up to 4 g/ml of vancomycin in the first 8 h of incubation was indicative of a VISA or VRSA phenotype since the longest detection time at 4 g/ml ever obtained for VISA or VRSA was 5.0 h. Strains showing positive growth at 2 g/ml but not at 4 g/ml in the first 8 h of incubation indicated an hVISA phenotype. Interestingly, microcalorimetric heat curves show that even though the MICs of VISA Mu50 and VISA PC3 as determined by routine conventional methods are the same at 8 g/ml, the characteristics of their antibiotic susceptibility profiles toward vancomycin are different. Indeed, Fig. 1C shows that PC3 exhibits a more homogenous resistance profile toward vancomycin than Mu50. In comparison to the growth control without antibiotic, only a slight lag in time to detection was observed for PC3 at 7 g/ml and 8 g/ml, whereas a delay was already noticed from 4 g/ml and upwards of 4 g/ml for Mu50. This parallels the results obtained by PAP, which indicate that almost the whole PC3 population was able to grow at 8 g/ml, whereas only subpopulations of the Mu50 strain are able to grow at 7 and 8 g/ml of vancomycin (19) .
Screening of clinical isolates. Using the aforementioned criteria established with the reference strains, we analyzed clinical isolates of MRSA with either a vancomycin-susceptible phenotype or a decreased susceptibility to vancomycin, as determined by the PAPs. The mean times to detection are shown in Table S1 in the supplemental material.
In the vancomycin-susceptible group, 19/20 (95%) isolates were correctly identified as VSSA by the microcalorimetry method and 1/20 (5%) isolates was misclassified as harboring decreased susceptibility to vancomycin. Indeed, for this isolate (LY 8), positive growth at 2 g/ml of vancomycin was detected after 6.2 h of incubation, even though this strain was classified as VSSA by the PAP. This might be due to the fact that in liquid medium, this isolate might exhibit better growth in the presence of an antibiotic than on the solid medium used for PAP determinations. In the group with decreased susceptibilities to vancomycin (4 hVISA and 5 VISA strains), 9/9 (100%) of the isolates were correctly detected by the microcalorimetry method.
Detection of sequential development of vancomycin-intermediate resistance leading to the first VISA isolate in Switzerland. A 63-year-old male patient was admitted to the intensive care unit (ICU) of our institution in June 2008 for myocardial infarction with refractory cardiogenic shock. Eight weeks later, a biventricular assist device (VAD) was implanted and the patient was put on the waiting list for heart transplantation. At that time, the patient was colonized on the skin by a MRSA (Fig. 2, MRSA 1) strain that was susceptible to vancomycin (AUC ratio of 0.6). Of note, among the other treatments, implantation of the VAD was done under vancomycin prophylaxis.
In February 2009, the patient received 2 weeks of vancomycin therapy for a MRSA urinary tract infection (the susceptibility profile was similar to MRSA 1). Two weeks after the discontinuation of vancomycin (March 2009), the patient developed a fever with chills and confusion. Purulent discharge was observed around the external line of the VAD, but imaging did not reveal the presence of an abscess around the VAD. Blood cultures, as well as the culture of the purulent discharge, were positive for a vancomycinsusceptible MRSA strain (MRSA 2; AUC ratio of 0.7). Vancomy- cin was started with a target trough plasma level of 15 g/ml. Sequential blood cultures were positive for MRSA until 12 days after the first positive blood culture. Rifampin was then added to the vancomycin therapy. A MRSA strain was isolated that showed vancomycin-intermediate resistance by PAP (MRSA 3; AUC ratio of 1.32). After 4 weeks of vancomycin and rifampin, therapy was switched to oral cotrimoxazole, which was planned to continue until heart transplantation.
In June 2009, while the patient was on cotrimoxazole, a control swab of nonpurulent discharge from the external line of the VAD grew a VISA strain with further reduced vancomycin susceptibility (MRSA 4; AUC ratio of 1.59). Since the patient had no fever and the characteristics of the discharge had not changed over the previous few weeks, no treatment was started, as the isolate was considered to be a colonizer.
Hence, because of persistent colonization of the biventricular assist device by MRSA, and the serial exposure to various antibiotic treatments (including vancomycin for MRSA bacteremic episodes), the original vancomycin-susceptible MRSA strain (MRSA 1) gradually evolved toward a VISA phenotype (MRSA 4). Of note, the amplified fragment length polymorphism analysis results indicated that all the MRSA isolates were clonal (data not shown). Relative to other countries, the MRSA prevalence in Switzerland is relatively low, and to the best of our knowledge, our results represent the identification of the first invasive clinical vancomycin-intermediate MRSA strain in Switzerland.
In addition to the PAPs (Fig. 2) , we performed microcalorimetric studies (Fig. 3) on the various MRSA isolates from this patient. The results clearly show that in parallel to the evolution of decreased vancomycin susceptibility detected by PAP, microcalorimetric heat flow curve profiles showed decreased susceptibilities to vancomycin. Interestingly, as can be seen from the heat flow curves without antibiotics (Fig. 3) , these 4 MRSA isolates exhibited a significantly slower growth phenotype than the other MRSA isolates tested in this study. Accordingly, even though MRSA 3 and MRSA 4 were classified as VISA by PAP, and the microcalorimetric detection times at 2 g/ml of vancomycin were Ͻ8 h, as expected (7.9 h and 5.9 h for the MRSA 3 and 4 strains, respectively), the detection times at 4 g/ml of vancomycin were above the values obtained for all the other VISA isolates presented in Table 1 (16.5 h and 10.3 h for the MRSA 3 and 4 strains, respectively). Thus, depending on the growth rate in liquid medium, the time-to-detection criteria might need to be adapted for strains exhibiting exceptionally slowly growing phenotypes.
Of note, compared to the measurements of bacterial growth by optical density at 600 nm (OD 600 ) using a spectrophotometer, the typical results showed that the growth curves performed in the presence of vancomycin concentrations of 2 g/ml did not appreciably change from baseline within 8 h (see Fig. S1 and materials and methods in the supplemental material), whereas the growth detection by microcalorimetry was achieved under these conditions within 8 h. Thus, the calorimetric method provides a more rapid differentiation of MRSA from VISA than standard spectrophotometry.
DISCUSSION
Microcalorimetry has recently been used to differentiate methicillin-susceptible S. aureus (MSSA) from MRSA (20) and to determine antibiotic susceptibility profiles (21) . The results presented in our study indicate that microcalorimetry can be used to rapidly detect vancomycin-nonsusceptible MRSA and might allow for faster antibiotic therapeutic adaptations for MRSA infections that do not respond well to standard vancomycin therapy.
Indeed, the current routine methods are either unsatisfactory or too time-consuming to provide information to clinicians in a timely manner. Because it is unrealistic to test all MRSA isolates found in a clinical microbiology laboratory by the current gold standard, PAP, laboratory algorithms, such as the one available on the CDC website (see http://www.cdc.gov/HAI/settings/lab/visa _vrsa_algorithm.html), have been developed for this purpose. Typically, 48 to 72 h is often required to provide results, and the expertise of a specialized laboratory might be necessary.
Our results show a reproducible differentiation between VSSA, hVISA, and VISA phenotypes on well-characterized reference strains. Since none of the hVISA, VISA, or VRSA strains studied was misclassified as VSSA, the microcalorimetry method was used to rule out a decreased vancomycin susceptibility phenotype in Ͻ8 h. Whether or not this method might also be useful to assess the susceptibility of MRSA to other antibiotics (e.g., daptomycin or linezolid) remains to be determined with specific resistant strains. For instance, a reduced susceptibility to daptomycin was detected in strains with a high vancomycin MIC, such as strain Mu50 (22) , whereas no resistance to linezolid was detected (data not shown).
New technologies that have been introduced into clinical microbiology laboratories, such as matrix-assisted laser desorption ionization-time of flight mass spectrometry for bacterial identification (23) or innovative methods for antibiotic susceptibility testing (24) , are aimed at reducing the delay that occurs in providing clinicians with useful information for patient care. Currently, the acquisition costs of multichannel microcalorimeters are high and these devices are therefore not suitable for routine diagnostic laboratories. However, with further developments that might reduce manufacturing costs, the introduction of microcalorimetry-based antibiotic susceptibil- ity determination might also be useful to rapidly adapt antimicrobial treatments and follow the development of resistance in clinical strains from patients, especially when undergoing long-lasting antibiotic treatments.
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